natgillin/translations-raw huggingface dataset:
The exposure to cobicistat was lower during pregnancy, potentially leading to suboptimal boosting of darunavir.
Izloženost kobicistatu je bila niža tijekom trudnoće, što potencijalno dovodi do suboptimalnog pojačanja darunavira.
In rodents the target organs identified were the haematopoietic system, the blood coagulation system, liver and thyroid.
U glodavaca, ciljni organi su bili hematopoetski sustav, sustav koagulacije krvi, jetra i štitnjača.
Atorvastatin, pravastatin, rosuvastatin (to lower cholesterol levels).
- atorvastatin, pravastatin, rosuvastatin (za snižavanje razina kolesterola).
Fluconazole Isavuconazole Itraconazole Posaconazole
Flukonazol Izavukonazol Itrakonazol Posakonazol
Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions.
Bolesnici s već postojećom disfunkcijom jetre, uključujući kronični aktivni hepatitis B ili C, imaju povećani rizik za nastanak poremećaja funkcije jetre uključujući teške i potencijalno fatalne jetrene nuspojave.
Rash considered by the investigator to be drug-related occurred at similar rates.
Osip koji je prema mišljenju ispitivača bio povezan s lijekom, pojavio se u sličnim stopama.
Patients should be instructed to take darunavir with low dose ritonavir within 30 minutes after completion of a meal.
Bolesnike se mora uputiti da uzimaju darunavir s niskom dozom ritonavira unutar 30 minuta nakon završetka obroka.
In vitro experiments with human liver microsomes (HLMs) indicate that darunavir primarily undergoes oxidative metabolism.
In vitro ispitivanja s humanim jetrenim mikrosomima pokazuju da darunavir primarno prolazi put oksidativnog metabolizma.
Haemophiliac patients should, therefore, be made aware of the possibility of increased bleeding.
Bolesnike s hemofilijom se stoga mora upozoriti na mogućnost pojačanog krvarenja.
It is recommended that HIV infected women must not breast-feed their infants because of both the possibility of your baby becoming infected with HIV through your breast milk and because of the unknown effects of the medicine on your baby.
Preporučuje se da žene zaražene HIV-om ne smiju dojiti djecu zbog mogućnosti prijenosa HIV-a na dijete putem majčina mlijeka te zbog nepoznatih učinaka koje lijek može imati na Vaše dijete.
Refer to section 4.4 if creatinine clearance is used for dose adjustment of emtricitabine or lamivudine.
Pogledajte dio 4.4 ako se klirens kreatinina koristi za prilagodbu doze emtricitabina ili lamivudina.
Methadone individual dose ranging from 55 mg to 150 mg once daily
Metadon pojedinačna doza u rasponu od 55 mg do 150 jedanput na dan
Co-administration with CYP3Ametabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects.
Istodobna primjena s koritkosteroidima koji se metaboliziraju putem CYP3A se ne preporučuje osim ako potencijalna korist za bolesnika ne prevladava rizik, i u tom je slučaju bolesnike potrebno nadzirati na sistemske učinke kortikosteroida.
What is Darunavir Krka?
Što je Darunavir Krka?
Darunavir in combination with ritonavir caused a reduction in the number of pups that exhibited the startle response on day 15 of lactation and a reduced pup survival during lactation.
Darunavir u kombinaciji s ritonavirom je uzrokovao smanjenje broja mladunčadi koja je pokazala odgovor na iznenadni podražaj 15. dana laktacije, a i smanjeno preživljavanje mladunčadi tijekom laktacije.
Pregnant or breast-feeding mothers should not take Darunavir Krka with ritonavir unless specifically directed by the doctor.
Trudnice ili dojilje ne smiju uzimati Darunavir Krka s ritonavirom osim ako to liječnik posebno ne odredi.
6/l (see section 4.2).
6/l (vidjeti dio 4.2).
C-darunavir with ritonavir showed that approximately 7.7% of the administered dose of darunavir is excreted in the urine unchanged.
C -darunavirom s ritonavirom pokazali su da se približno 7,7% primijenjene doze darunavira izluči u mokraći u nepromijenjenom obliku.
Darunavir was not mutagenic or genotoxic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames), chromosomal aberration in human lymphocytes and in vivo micronucleus test in mice.
Darunavir nije bio mutagen ili genotoksičan u setu in vitro i in vivo testova uključujući reverznu bakterijsku mutaciju (Ames), kromosomsku aberaciju u ljudskim limfocitima te in vivo mikroneukleusni test u miševa.
Increased concentrations of quetiapine may lead to coma (see section 4.3).
Povišene koncentracije kvetiapina mogu dovesti do kome (vidjeti dio 4.3).
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Ako primijetite bilo koji simptom infekcije ili drugi simptom poput mišićne slabosti, slabosti koja počinje u šakama i stopalima te se širi gore prema trupu tijela, lupanja srca, tremora ili hiperaktivnosti, molimo Vas odmah obavijestite liječnika i zatražite potrebno liječenje.
It is not known whether darunavir is excreted in human milk.
Nije poznato izlučuje li se darunavir u majčino mlijeko u ljudi.
Animal toxicology studies have been conducted at exposures up to clinical exposure levels with darunavir alone, in mice, rats and dogs and in combination with ritonavir in rats and dogs.
Provedena su toksikološka ispitivanja na životinjama, pri izloženostima do razina kliničke izloženosti sa samim darunavirom, na miševima, štakorima i psima, a u kombinaciji s ritonavirom na štakorima i psima.
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Darunavir Krka.
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Darunavir Krka.
Rifapentine and rifampicin are strong CYP3A inducers and have been shown to cause profound decreases in concentrations of other protease inhibitors, which can result in virological failure and resistance development (CYP450 enzyme induction).
Rifapentin i rifampicin su snažni induktori CYP3A i pokazano je da uzrokuju značajna sniženja koncentracija drugih inhibitora proteaze, što može rezultirati virološkim neuspjehom i razvojem rezistencije (indukcija enzima CYP450).
Carbamazepine concentrations should be monitored and its dose should be titrated for adequate response.
Mora se pratiti koncentracije karbamazepina, a dozu je potrebno titrirati do odgovarajućeg terapijskog odgovora.
After therapy has been initiated, the dose or dosage form must not be changed or therapy must not be stopped without instruction of the doctor.
Nakon što je terapija započela, dozu ili oblik doziranja lijeka ne smijete mijenjati a terapija se ne smije prekinuti bez da Vam je to savjetovao liječnik.
(Rifabutin is an inducer and substrate of CYP3A.)
(Rifabutin je induktor i supstrat CYP3A).
You will require a different dose of Darunavir Krka which cannot be administered with these 600 milligram tablets.
Trebat ćete drugačiju dozu lijeka Darunavir Krka koja se ne može primijeniti ovim tabletama od 600 miligrama.
Infections and infestations uncommon herpes simplex
Infekcije i infestacije manje često herpes simpleks
The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 80-125% range (not determined as “ND”).
Smjer strelice za svaki farmakokinetički parametar utemeljen je na 90%-tnom intervalu pouzdanosti omjer geometrijskih srednjih vrijednosti unutar granice (↔), ispod (↓) ili iznad (↑) raspona 80-125% (nije određeno je označeno kao „NO“).
TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA < 400 copies/ml) IAS-USA lists
TLOVR ne-VF cenzoriran algoritam na temelju HIV-1 RNA < 50 kopija/ml, osim za ispitivanje TITAN (HIV-1 RNA < 400 kopija/ml) IAS-USA liste
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
NARKOTIČKI ANALGETICI / LIJEČENJE OVISNOSTI O OPIOIDNIM LIJEKOVIMA
Never suppressed subjects
Ispitanici u kojih nikada nije bilo supresije
Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-Odesacetyl metabolite) was increased 1.6fold, while Cmax remained comparable.
Osim toga, AUC zbroja aktivnih komponenti rifabutina (izvorni lijek + 25-O-desacetil metabolit) povišen je 1,6 puta, dok je Cmax ostala usporediva.
Tell your doctor if you develop any of the following side effects.
Obavijestite liječnika ako dobijete bilo koju od sljedećih nuspojava.
4.4Special warnings and precautions for use
4.4 Posebna upozorenja i mjere opreza pri uporabi
No pharmacokinetic data are available in patients with severe hepatic impairment.
Nisu dostupni farmakokinetički podaci za bolesnike s teškim oštećenjem funkcije jetre.
The rashes observed in clinical studies were mild to moderate in severity and did not result in discontinuation of therapy (see section 4.4).
Osipi opaženi u kliničkim ispitivanjima bili su blage do umjerene težine i i nisu rezultirali prekidom terapije (vidjeti dio 4.4).
For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.
- Za liječenje HIV-1 infekcije u pedijatrijskih bolesnika u dobi od 3 godine i težine najmanje 15 kg.
Of the 44 patients taking ritonavir oral solution, 27 switched to the 100 mg capsule formulation and exceeded the weightbased ritonavir dose without changes in observed safety.
Od 44 bolesnika koji su uzimali ritonavir oralnu otopinu, njih 27 prešlo je na 100 mg kapsule i time prešlo preporučeno doziranje na temelju tjelesne težine, a da pri tome nisu opažene promjene u sigurnosti.
The terminal elimination half-life of darunavir was approximately 15 hours when combined with ritonavir.
Poluvrijeme eliminacije darunavira bilo je približno 15 sati kad se kombinirao s ritonavirom.
Tablet dimension: 17 x 8.5 mm.
Dimenzija tablete: 17 x 8,5 mm.
In the study, patients who were at risk of discontinuing therapy due to intolerance of ritonavir oral solution (e.g. taste aversion) were allowed to switch to the capsule formulation.
U ispitivanju je bilo dopušteno bolesnicima koji su bili pod rizikom od prekida terapije zbog nepodnošenja ritonavir oralne otopine (npr. nepodnošenje okusa) prijeći na oblik u kapsulama.
PI RAMs
IP RAM
Isolates with baseline FC ≤ 10 are susceptible; isolates with FC > 10 to 40 have decreased susceptibility; isolates with FC > 40 are resistant (see Clinical results).
Izolati s početnim PV ≤ 10 puta su osjetljivi; izolati s PV > 10 puta do 40 puta imaju smanjenu osjetljivost; izolati s PV > 40 puta su rezistentni (vidjeti Kliničke rezultate).
No mother to child transmission occurred in the infants born to the 31 subjects who stayed on the antiretroviral treatment through delivery.
Prijenos bolesti s majke na dijete nije zabilježen u novorođenčadi 31 ispitanice, koje su ostale na antiretrovirusnoj terapiji tijekom poroda.
Ethinylestradiol (3 mg/0.02 mg once daily)
Etinilestradiol (3 mg/0,02 mg jedanput na dan)
Unlike ritonavir, cobicistat does not have inducing effects on enzymes or transport proteins (see section 4.5).
- Za razliku od ritonavira, kobicistat nema inducirajuće učinke na enzime ili prijenosne proteine (vidjeti dio 4.5).
In repeated-dose toxicology studies in mice, rats and dogs, there were only limited effects of treatment with darunavir.
U ispitivanjima toksičnosti ponovljenih doza u miševa, štakora i pasa, postojali su samo ograničeni učinci na liječenje darunavirom.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART).
Prijavljeni su slučajevi osteonekroze, osobito u bolesnika s općepoznatim faktorima rizika, uznapredovalom HIV bolešću ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji.
Even when you feel better, do not stop taking Darunavir Krka.
Čak i ako se osjećate bolje, nemojte prestati uzimati lijek Darunavir Krka.
However, for unbound (i.e. active) darunavir, the pharmacokinetic parameters were less reduced during pregnancy compared to postpartum, due to an increase in the unbound fraction of darunavir during pregnancy compared to postpartum.
Ipak, farmakokinetički parametri nevezanog darunavira (tj. aktivnog), bili su manje sniženi tijekom trudnoće u usporedbi s postpartalnim razdobljem, zbog povišenja nevezane frakcije darunavira tijekom trudnoće u odnosu na postpartalno razdoblje.
The lowest rates of developing resistant HIV virus are observed in ART-naïve patients who are treated for the first time with darunavir in combination with other ART.
Najniže stope razvoja rezistentnog HIV virusa opažene su u bolesnika prethodno neliječenih ART-om i koji su prvi put liječeni darunavirom u kombinaciji s drugim ART-om.
There is no specific antidote for overdose with darunavir.
Ne postoji poseban antidot za predoziranje darunavirom.
Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency.
U bolesnica koje koriste estrogene kao hormonsku nadomjesnu terapiju, trebaju se klinički pratiti znakovi estrogenske deficijencije.
Virologic response was defined as a decrease in plasma HIV-1 RNA viral load of at least 1.0 log10 versus baseline.
Virološki odgovor bio je definiran kao sniženje HIV-1 RNK virusnog opterećenja u plazmi od najmanje 1,0 log10 naspram početnih vrijednosti.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straβe 5, 27472 Cuxhaven, Germany
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija TAD Pharma GmbH, Heinz-Lohmann-Straβe 5, 27472 Cuxhaven, Njemačka
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels.
Podaci iz istodobne primjene parenteralnog midazolama s drugim inhibitorima proteaza ukazuju na mogući porast razine midazolama u plazmi 3-4 puta.
The exposure-adjusted rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100 patient-years (PYR), respectively; and for drug-related rash were 2.4, 1.1, and 2.3 per 100 PYR, respectively.
Stope osipa prilagođene izloženosti (svih uzroka) bile su 10,9; 4,2 odnosno 3,8 na 100 bolesnik-godina, a za osip povezan s lijekom bile su 2,4, 1,1 odnosno 2,3 na 100 bolesnik-godina.
In the dog, no major toxicity findings or target organs were identified up to exposures equivalent to clinical exposure at the recommended dose.
U pasa nije nađena veća toksičnost ciljnih organa pri izloženostima jednakim kliničkoj izloženosti pri preporučenoj dozi.
The frequency of this is unknown (see section 4.4).
Učestalost ovog nije poznata (vidjeti dio 4.4).
Type AE Type C
Tip AE
Ciclosporin Sirolimus Tacrolimus Everolimus
Ciklosporin Sirolimus Takrolimus Everolimus
These patients received darunavir/ritonavir twice daily in combination with other antiretroviral agents (see section 4.2 for dosage recommendations per body weight).
Ovi bolesnici primali su darunavir/ritonavir dvaput na dan u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 4.2 za preporuke o doziranju prema tjelesnoj težini).
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolesnike se mora savjetovati da potraže medicinski savjet ako osjete stalne tupe i povremeno jače bolove u zglobovima, ukočenost zglobova ili teškoće pri kretanju.
In a pre- and postnatal development assessment in rats, darunavir with and without ritonavir, caused a transient reduction in body weight gain of the offspring pre-weaning and there was a slight delay in the opening of eyes and ears.
U procjeni prenatalnog i postnatalnog razvoja u štakora, darunavir sa ili bez ritonavira, uzrokovao je prolazno smanjenje dobivanja tjelesne težine u mladunčadi do prestanka laktacije, a također je došlo do nešto odgođenog otvaranja očiju i ušiju.
It is not possible to administer all paediatric dosages with this product.
Nije moguće primijeniti sva pedijatrijska doziranja ovim lijekom.
Adverse reactions observed with darunavir/ritonavir in clinical trials and post-marketing
Nuspojave zabilježene s darunavirom/ritonavirom u kliničkim ispitivanjima i postmarketinškom praćenju
The efficacy and safety of the use of darunavir with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir, nelfinavir and tipranavir) has not been established in HIV patients.
Djelotvornost i sigurnost primjene darunavira sa 100 mg ritonavira s bilo kojim drugim IP HIV-a (npr. (fos)amprenavir, nelfinavir i tipranavir) nisu ustanovljene u HIV bolesnika.
There have been reports of increased spontaneous bleeding in haemophiliac patients receiving antiretroviral protease inhibitors (see section 4.4).
Prijavljeno je pojačano spontano krvarenje u bolesnika s hemofilijom koji primaju antiretrovirusne inhibitore proteaze (vidjeti dio 4.4).
Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have been reported with the use of protease inhibitors, particularly in combination with NRTIs.
Povišeni CPK, mialgija, miozitis i rijetko rabdomioliza bili su prijavljeni uz primjenu inhibitora proteaze, osobito u kombinaciji s NRTI.
Exposure to darunavir was higher in HIV-1 infected patients than in healthy subjects.
Izloženost darunaviru bila je viša u bolesnika inficiranih s HIV-1 nego u zdravih ispitanika.
Imputations according to the TLOVR algorithm Last Observation Carried Forward imputation 95% confidence intervals.
Pripisane vrijednosti izračunate prema TLOVR algoritmu Prenijeta pripisana vrijednost zadnjeg opažanja 95% intervali pouzdanosti
In the virologic failures of the ARTEMIS trial no cross-resistance with other PIs was observed.
Kod viroloških neuspjeha u kliničkom ispitivanju ARTEMIS nije uočena križna rezistencija s drugim IP.
Interactions between darunavir/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below.
Interakcije između darunavira/ritonavira i antiretrovirusnih te ne-antiretrovirusnih lijekova navedene su u donjoj tablici.
Due to uncertainties regarding the rate of development of the human blood brain barrier and liver enzymes, darunavir with low dose ritonavir should not be used in paediatric patients below 3 years of age.
S obzirom na nesigurnost vezanu uz poznavanje brzine razvoja ljudske krvnomoždane barijere i jetrenih enzima, darunavir s niskom dozom ritonavira ne smije se primjenjivati pedijatrijskim bolesnicima mlađima od 3 godine starosti.
common angioedema, pruritus, urticaria rare drug reaction with eosinophilia and systemic symptoms*, Stevens-Johnson syndrome*
često angioedem, pruritus, urtikarija rijetko reakcija na lijek s eozinofilijom i sistemskim simptomima*, Stevens-Johnsonov sndrom*
(CYP3A inhibition)
(CYP3A inhibicija)
HMG CO-A REDUCTASE INHIBITORS Lovastatin
INHIBITORI HMG CO-A REDUKTAZE Lovastatin
No human data on the effect of darunavir on fertility are available.
Nema dostupnih podataka o učinku darunavira na plodnost u ljudi.
It is therefore important to talk to your doctor if you develop a rash.
Stoga je važno da razgovarate s liječnikom ako se pojavi osip.
After 2 years administration of darunavir at exposures at or below the human exposure, kidney changes were observed in mice (nephrosis) and rats (chronic progressive nephropathy).
Nakon 2 godine primjene darunavira pri izloženostima koja je jednaka ili ispod izloženosti u ljudi, primijećene su promjene na bubrezima u miševa (nefroza) i štakora (kronična progresivna nefropatija).
The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown.
Učinci visoke sistemske izloženosti flutikazona na razine ritonavira u plazmi nisu poznati.
You must take Darunavir Krka every day and always in combination with 100 milligram of ritonavir and with food.
Lijek Darunavir Krka morate uzimati svaki dan i uvijek u kombinaciji sa 100 miligrama ritonavira i s hranom.
Several of the interaction studies have been performed with darunavir at lower than recommended doses.
Provedeno je nekoliko ispitivanja interakcija s darunavirom u dozama nižima od preporučenih.
At the highest tested doses, the systemic exposures (based on AUC) to darunavir were between 0.4- and 0.7-fold (mice) and 0.7- and 1-fold (rats), relative to those observed in humans at the recommended therapeutic doses.
Pri najvišim ispitivanim dozama, sistemske izloženosti darunaviru (temeljene na AUC), bila je veća između 0,4 i 0,7 puta (u miševa) te 0,7 i 1 puta (u štakora), u odnosu na opaženu izloženost u ljudi pri preporučenom terapijskim dozama.
Increasing baseline darunavir fold change in EC50 (FC) was associated with decreasing virologic response.
Povišenje početne promjene vrijednosti (PV) EC50 darunavira bilo je povezano sa smanjenim virološkim odgovorom.
Changes were observed in liver (hepatocyte hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular hypertrophy).
Primjećene su promjene na jetri (hipertrofija hepatocita, vakuolizacija, povišeni enzimi jetre) i štitnjači (hipertrofija folikula).
Darunavir/ritonavir may be considered as an alternative.
Darunavir/ritonavir mogu se uzeti u obzir kao zamjena.
Darunavir/ritonavir should not be used in children with a body weight of less than 15 kg as the dose for this population has not been established in a sufficient number of patients (see section 5.1).
Darunavir /ritonavir se ne smije primjenjivati u djece s tjelesnom težinom manjom od 15 kg, jer doza za ovu populaciju nije ustanovljena na dovoljnom broju bolesnika (vidjeti dio 5.1).
Limited information is available in this population, and therefore, darunavir should be used with caution in this age group (see sections 4.4 and 5.2).
Za ovu populaciju dostupne su ograničene informacije, stoga se darunavir u toj dobnoj skupini mora primjenjivati s oprezom (vidjeti dijelove 4.4 i 5.2).
║ based on published data with darunavir/ritonavir rosuvastatin AUC ↑ 93% rosuvastatin Cmax ↑ 277% rosuvastatin Cmin ND
║ na temelju objavljenih podataka s darunavirom/ritonavirom rosuvastatin AUC ↑ 93% rosuvastatin Cmax ↑ 277% rosuvastatin Cmin NO
ANTINEOPLASTICS Dasatinib
ANTINEOPLASTICI Dasatinib
These results were confirmed in the analyses of data at 96 weeks of treatment in the ARTEMIS trial.
Ti su rezultati potvrđeni analizom podataka u 96. tjednu liječenja u ispitivanju ARTEMIS.
People taking Darunavir Krka may develop a skin rash.
Osobe koje uzimaju Darunavir Krka mogu razviti kožni osip.
Darunavir FC was less than 10 for 90% of 3,309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that viruses resistant to most PIs remain susceptible to darunavir.
PV darunavira bila je manja od 10 puta za 90% od 3309 kliničkih izolata rezistentnih na amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, sakvinavir i/ili tipranavir pokazujući da virusi rezistentni na većinu IP-a ostaju osjetljivi na darunavir.
20 mg once daily
20 mg jedanput na dan
Single doses up to 3,200 mg of darunavir as oral solution alone and up to 1,600 mg of the tablet formulation of darunavir in combination with ritonavir have been administered to healthy volunteers without untoward symptomatic effects.
Jednokratne doze do 3200 mg darunavira u obliku oralne otopine same i do 1600 mg darunavira u obliku tableta u kombinaciji s ritonavirom primjenjivale su se zdravim dobrovoljcima bez neželjenih simptomatskih učinaka.
Elimination After a 400/100 mg
Nakon doze od 400/100 mg